Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (31-40 of 184) with videos related to

Pageof 19
Sort By:
Plos Pathogens|August 26, 2020
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatmentHadega A Aamer, Jan McClure, Daisy Ko, et al.
AIDS (London, England)|May 15, 2010
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infectionJudith J Lok, Ronald J Bosch, Constance A Benson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2011
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavirBrian J Kirby, Ann C Collier, Evan D Kharasch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2017
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B StudyRobert A Parker, Dustin J Rabideau, Paul E Sax, et al.
Journal of Pharmaceutical Sciences|March 18, 2018
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous InjectionLisa A McConnachie, Loren M Kinman, Josefin Koehn, et al.
AIDS (London, England)|August 31, 2023
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectableSimone Perazzolo, Zachary R Stephen, Masa Eguchi, et al.
AIDS (London, England)|January 19, 2017
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasmaJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
AIDS Research and Therapy|February 26, 2022
The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United StatesAaron T Brah, Douglas Barthold, Brett Hauber, et al.
Plos One|December 24, 2011
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionJoanne D Stekler, Giovanina M Ellis, Jacquelyn Carlsson, et al.
AIDS (London, England)|December 3, 2010
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohortMarlene Smurzynski, Kunling Wu, Scott Letendre, et al.
Pageof 19

Showing results (31-40 of 184) with videos related to

Sort By:
Pageof 19
Plos Pathogens|August 26, 2020
Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatmentHadega A Aamer, Jan McClure, Daisy Ko, et al.
AIDS (London, England)|May 15, 2010
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infectionJudith J Lok, Ronald J Bosch, Constance A Benson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 21, 2011
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavirBrian J Kirby, Ann C Collier, Evan D Kharasch, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2017
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B StudyRobert A Parker, Dustin J Rabideau, Paul E Sax, et al.
Journal of Pharmaceutical Sciences|March 18, 2018
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous InjectionLisa A McConnachie, Loren M Kinman, Josefin Koehn, et al.
AIDS (London, England)|August 31, 2023
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectableSimone Perazzolo, Zachary R Stephen, Masa Eguchi, et al.
AIDS (London, England)|January 19, 2017
Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasmaJohn C Kraft, Lisa A McConnachie, Josefin Koehn, et al.
AIDS Research and Therapy|February 26, 2022
The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United StatesAaron T Brah, Douglas Barthold, Brett Hauber, et al.
Plos One|December 24, 2011
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionJoanne D Stekler, Giovanina M Ellis, Jacquelyn Carlsson, et al.
AIDS (London, England)|December 3, 2010
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohortMarlene Smurzynski, Kunling Wu, Scott Letendre, et al.
Pageof 19